Myocarditis after RNA-based vaccines for coronavirus. Views equals page views plus PDF downloads. These cookies may also be used for advertising purposes by these third parties. Clipboard, Search History, and several other advanced features are temporarily unavailable. Regarding health equity considerations, racial and ethnic minority groups have higher rates of COVID-19 and severe disease*****; potential changes in vaccine policy, or anything that would affect vaccination coverage for adolescents or young adults, might disproportionately affect those groups with the highest rates of poor COVID-19 outcomes. Bookshelf The rates of myocarditis were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively). % Myocarditis has been linked with other vaccines, such as those that prevent influenza (flu), smallpox, and shingles.6. Table 2. The rate is significantly higher - 450 cases per million infections. Diagnosis and Management of Myocarditis in Children: A Scientific Statement from the American Heart Association. ; MIS-C Incidence Authorship Group. According to the US Centers for Disease Control and Prevention, myocarditis/pericarditis rates are 12.6 cases per million doses of second-dose mRNA vaccine among individuals 12 to 39 years of age. Mary Chamberland, Thomas Clark, Amanda Cohn, Frank DeStefano, Ruth Gallego, Alice Guh, Theresa Harrington, Fiona P. Havers, Lauri Hicks, Amelia Jazwa, Tara Johnson, Brian Kit, Paige Marquez, Sarah Mbaeyi, Elaine Miller, Hannah Rosenblum, Monica Parise, Kadam Patel, Pragati Prasad, David Shay, Jamila Shields, Christopher A. Taylor, Joshua Wong, CDC COVID-19 Response Team; Clinical Immunization Safety Assessment (CISA) Project; Vaccine Safety Datalink; Center for Biologics Evaluation and Research, Food and Drug Administration; Voting members of the Advisory Committee on Immunization Practices: Kevin A. Ault, University of Kansas Medical Center; Lynn Bahta, Minnesota Department of Health; Henry Bernstein, Zucker School of Medicine at Hofstra/Northwell Cohen Childrens Medical Center; Beth Bell, University of Washington, Seattle, Washington; Wilbur Chen, University of Maryland School of Medicine; Sharon E. Frey, Saint Louis University Medical School; Camille Kotton, Harvard Medical School; Sarah Long, Drexel University College of Medicine; Katherine A. Poehling, Wake Forest School of Medicine; Pablo J. Snchez, The Research Institute at Nationwide Childrens Hospital. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. Vaccination prevents most hospitalizations and deaths due to COVID-19. Among patients in a large Israeli health care system who had received at least one dose of the BNT162b2 mRNA vaccine, the estimated incidence of myocarditis was 2.13 cases per 100,000 persons; the . Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. Men and boys between the ages of 16 and 29 have been most often affected by COVID-19vaccine-related myocarditis, usually a few days after their second dose.5 Myocarditis may be due to their strong immune response to the vaccine. Myocarditis is very uncommon, but it has been on the rise since the pandemic began. The vaccine product-specific EUA fact sheet should be provided to all vaccine recipients and their caregivers before vaccination with any authorized COVID-19 vaccine. Impact of COVID-19 on Cardiovascular Disease. The crude reporting rates for cases of myocarditis within 7 days after COVID-19 vaccination exceeded the expected rates of myocarditis across multiple age and sex strata. Even in this group, though, heart inflammation is seven or eight times more common after SARS-CoV-2 infection.10 And the data suggest that young adults with myocarditis possibly linked with COVID-19 vaccines recover quickly with supportive care.11. In young people aged 12-17 years (boys and girls combined), the rate of myocarditis or myopericarditis in Denmark was 1 per 100 000 with BNT162b2 compared with 18.5 per 100 000 in Hong Kong,3 and roughly 7 per 100 000 in Israel (ages 16-19 years).2 In 12-39 year old males after the second dose of BNT162b2, the incidence of myocarditis or . Association Between Myocarditis and Mortality in COVID-19 Patients in a Large Registry. COVID-19 vaccines lower the risk of life-threatening heart problems and other serious health issues. Six awards are related to COVID-19related myocarditis. Recent research about myocarditis, . Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. When reported, the cases have especially been in adolescents and young adult males within several days after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna). JAMA Netw Open 2021;4:e2116420. Wong HL, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, Secora A, McMahill-Walraven CN, Lu Y, Wu Y, Ogilvie RP, Reich C, Djibo DA, Wan Z, Seeger JD, Akhtar S, Jiao Y, Chillarige Y, Do R, Hornberger J, Obidi J, Forshee R, Shoaibi A, Anderson SA. Some people may have minimal or no symptoms. The analysis assumed 95% vaccine effectiveness of 2 doses of a mRNA COVID-19 vaccine in preventing COVID-19 cases and hospitalization and assessed outcomes for a 120-day period. <> and transmitted securely. 5 Vaccine-linked myocarditis is less likely to cause lingering heart problems than myocarditis due to COVID-19 illness. The rates of myocarditis cases were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 . No alternatives to mRNA COVID-19 vaccines for adolescents will be available for the foreseeable future, and vaccination of adolescents offers protection against COVID-19 that can be important for returning to educational, social, and extracurricular activities. More information is available, Travel requirements to enter the United States are changing, starting November 8, 2021. Online ahead of print. mRNA Vaccine Technology: A Promising Idea for Fighting HIV, Testing of mRNA HIV vaccines in humans is underway. If you have concerns about COVID-19 vaccination, talk with your healthcare provider or your childs doctor, nurse, or clinic. As of now, the FDA Fact Sheet for Moderna's shot says "Myocarditis and pericarditis have occurred . Cooper LT Jr. Myocarditis. Its important to remember that any vaccine can cause side effects. 2022 Jul 13;378:e069445. endobj Observed cases of myocarditis reported to VAERS after Moderna dose 2, 7-day risk period (N=216)* Age group, years Females Males Cases of myopericarditis, expected Cases of . July 5, 2022, U.S. Department of Health and Human Services, Benefits of COVID-19 vaccines outweigh a very small risk of heart complications, You can learn more about myocarditis symptoms, diagnosis, and treatment from the NHLBI, Countermeasures Injury Compensation Program, Researching COVID to Enhance Recovery (RECOVER), CONNECTS-Collaborative Cohort of Cohorts for COVID-19 Research (CONNECTS-C4R), https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total, https://doi.org/10.1161/CIR.0000000000001001, https://doi.org/10.1038/s41591-021-01630-0, https://doi.org/10.1016/j.hrtlng.2020.08.013, https://doi.org/10.1007/s12471-022-01677-9, https://doi.org/10.1016/j.vaccine.2020.12.046, https://doi.org/10.1016/j.ijcard.2022.01.037, https://doi.org/10.1007/s00392-022-02007-0, https://doi.org/10.1016/j.mayocpiqo.2021.12.006, https://doi.org/10.1177/01410768211052589, https://doi.org/10.1101/2021.10.05.21264581. The CDC also needs to recommend . CDC and its partners are actively monitoring reports of myocarditis and pericarditis after COVID-19 vaccination. January 07, 2022 The risk of myocarditis after immunization with mRNA-based vaccines against SARS-CoV-2 raised concerns when it came to light in early 2021. FLEG: Yes, but this is rare, and the symptoms are usually mild. * This analysis evaluated direct benefits and harms, per million second doses of mRNA COVID-19 vaccine given in each age group, over 120 days. Vaccine 2015;33:4398405. government site. When reported, the cases have especially been in adolescents and young adult males within several days after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna). The ACIP discussion concluded that 1) the benefits of vaccinating all recommended age groups with mRNA COVID-19 vaccine clearly outweigh the risks of vaccination, including the risk of myocarditis after vaccination; 2) continuing to monitor outcomes of myocarditis cases after COVID-19 vaccination is important; and 3) providers and the public should be informed about these myocarditis cases and the use of COVID-19 vaccines. Among 192 405 448 persons receiving a total of 354 100 845 mRNA-based COVID-19 vaccines during the study period, there were 1991 reports of myocarditis to VAERS and 1626 of these reports met the case definition of myocarditis. 8600 Rockville Pike National Library of Medicine If you need to go back and make any changes, you can always do so by going to our Privacy Policy page. Using myocarditis cases reported to VAERS with onset within 7 days after dose 2 of an mRNA vaccine, crude reporting rates (i.e., using confirmed and unconfirmed cases) per million second dose recipients were calculated using national COVID-19 vaccine administration data as of June 11, 2021. The researchers noted 9.7 myocarditis cases per 100,000 person-years for unvaccinated males and 4.3 per 100,000 for females. The vaccines are very effective against severe COVID-19 and protect your heart from the serious health consequences of the disease. 2021 Oct 1;6(10):1202-1206. doi: 10.1001/jamacardio.2021.2833. Myocarditis. ** The ACIP COVID-19 Vaccines Safety Technical (VaST) Work Group, comprising independent vaccine safety expert consultants, had also reviewed safety data on myocarditis after receipt of mRNA COVID-19 vaccines at its weekly meetings. ACIP emphasized the importance of informing vaccination providers and the public about the benefits and the risks, including the risk for myocarditis after COVID-19 vaccination, particularly for males aged 1229 years. In those aged under 18 years, the reported rate for heart inflammation (myocarditis and pericarditis) was 13 per million first doses and 8 per million second doses of the monovalent. While the researchers did observe a higher risk among people that got the Moderna shot, it was still a relatively small risk. The most common treatment was nonsteroidal anti-inflammatory drugs (589/676; 87%). Expected rates of myocarditis by age and sex were calculated using 2017-2019 claims data. After reports of myocarditis, the work group met twice to review clinical trial and postauthorization safety data for myocarditis after receipt of mRNA COVID-19 vaccines. Autopsy cases may be classified as confirmed clinical myocarditis on the basis of meeting histopathologic criteria if no other identifiable cause. To meet the ECG or rhythm monitoring criterion, a probable case must include at least one of 1) ST-segment or T-wave abnormalities; 2) Paroxysmal or sustained atrial, supraventricular, or ventricular arrhythmias; or 3) AV nodal conduction delays or intraventricular conduction defects. Using either the original or the revised Lake Louise criteria. All EUA documents for COVID-19 vaccines, including fact sheets, are available at https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccinesexternal icon. The U.S. Food and Drug Administration on Friday added a warning to patient and provider fact sheets for the Pfizer and Moderna Covid-19 vaccines to indicate a rare risk of heart inflammation. The EUA fact sheets should be provided before vaccination; in addition, CDC has developed patient and provider education materials about the possibility of myocarditis and symptoms of concern, to ensure prompt recognition and management of myocarditis. An analysis of 51 patients with possible or confirmed myocarditis showed that 70% were male, and the average age was 56. endobj These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests. A small number of myocarditis and pericarditis cases have been reported for booster doses. FOIA All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Evidence suggests that AstraZeneca and Novavax are probably associated with a small increased risk of myocarditis and pericarditis. Information about CDCs ongoing study of myocarditis after COVID-19 vaccination can be found here: Investigating Long-Term Effects of Myocarditis | CDC. At that meeting, a chart showed that through early June, there was a higher rate of myocarditis among people who received Moderna than Pfizer-BioNTech about 20 per 1 million doses for. in July asked Pfizer-BioNTech and Moderna to enroll more children in their clinical trials in order to detect less common side effects. For Moderna's vaccine, rates of myocarditis or pericarditis overall were 23 cases per million first doses and 62.5 cases per million second doses. Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myocarditis expected. The risk after both doses of the Moderna vaccine in people age 18 to 39 was as much as 37 times as high as in the general population, and the rate after two doses of the Pfizer-BioNTech vaccine. Between 2001 and 2020, the Institute has funded 139 myocarditis studies at a cost of $43.6 million. Information on how to submit a report to VAERS is available at https://vaers.hhs.gov/index.htmlexternal icon or 1-800-822-7967. Reports of Guillain-Barr Syndrome After COVID-19 Vaccination in the United States. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page. The ACIP COVID-19 Vaccines Work Group, comprising experts in infectious diseases, vaccinology, vaccine safety, public health, and ethics, has held weekly meetings since April 2020 to review COVID-19 surveillance data, evidence for vaccine efficacy and safety, and implementation considerations for COVID-19 vaccination programs. It affects fewer than 20 people per 1,000,000 COVID-19 vaccinations.3,5,7 Only the mRNA vaccines (Pfizer-BioNTech and Moderna) have been linked with myocarditis. A non-peer-reviewed retrospective paper, released as a pre-print, analyzed the rate of post-vaccination cardiac myocarditis in children aged 12-15 and 16-17 years who had received mRNA COVID . Myocarditis linked with COVID-19 illness may also be more severe because these patients are usually older and have other health conditions that increase their risk of complications. The text reads: "Myocarditis is irreversible. Your health care provider can provide more information thats specific to your situation. On June 23, 2021, the Advisory Committee on Immunization Practices concluded that the benefits of COVID-19 vaccination to individual persons and at the population level clearly outweighed the risks of myocarditis after vaccination. 2 0 obj Corresponding author: Sara E. Oliver, yxo4@cdc.gov. "If you're focused on heart inflammation, the safer bet is to take the vaccine," said Mendel Singer at Case Western Reserve University in Ohio, who helped carry out the study. Most patients with myocarditis or pericarditis who received care responded well to medicine and rest and felt better quickly. They also recover normal heart function sooner.12. It is unclear how many of these cases are a direct consequence of the vaccine versus coincidental. The Researching COVID to Enhance Recovery (RECOVER) Initiative is taking place at 80 centers across the country. To receive email updates about COVID-19, enter your email address: We take your privacy seriously. COVID-19 is more likely than vaccines to cause myocarditis, and symptoms and outcomes are often worse. : Myocarditis is an inflammation of the heart muscle. US researchers say teenagers are more likely to get vaccine-related myocarditis than end up in hospital with Covid Skip to main content Skip to navigation Print subscriptions We dont know exactly how often this happens, but one study estimated that myocarditis affects about 40 people out of every 1,000,000 people who test positive for COVID-19.3 However, myocarditis is much more common in patients hospitalized for COVID-19 (226 per 100,000). Reports of myocarditis and pericarditis after vaccination are rare. Myocarditisisinflammation of the heart muscle. Were currently supporting two large studies looking at long-term effects of COVID-19, including myocarditis and other heart conditions. At the time of this report, 323 of these 484 cases were determined to meet criteria in CDCs case definitions for myocarditis, pericarditis, or myopericarditis by provider interview or medical record review (Table 1). Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Myocarditis rates were highest after the second vaccination dose in young males between 12 and 15 years of age (70.7 per million doses of the BNT162b2 vaccine), in adolescent males age 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men age 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine . The Pfizer and Moderna mRNA vaccines are available in the U.S. Dr Schlaudecker reported receiving grants from Pfizer and receiving personal fees from Sanofi Pasteur. People who experience a serious side effect of a vaccine or other medical products for COVID-19 may be eligible for compensation under the federal Countermeasures Injury Compensation Program. Su, J. R., McNeil, M. M., Welsh, K. J., Marquez, P. L., Ng, C., Yan, M., & Cano, M. V. (2021). Unable to load your collection due to an error, Unable to load your delegates due to an error. the date of publication. I doubt we'll ever know. A., & American Heart Association Pediatric Heart Failure and Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young and Stroke Council (2021). HHS Vulnerability Disclosure, Help FLEG: Vaccination helps protect people from getting sick or severely ill with COVID-19 and helps protect those around them. 76% were classified as mild and 22% intermediate. You can review and change the way we collect information below. Broken down by age and sex, a second dose of the Moderna vaccine was associated with a higher rate of myocarditis or pericarditis compared with a second dose of the Pfizer/BioNTech vaccine among males ages 18 to 24 (adjusted rate ratio 6.6; 95% CI 3.3-13.2) and 25 to 39 (adjusted rate ratio 5.1; 95% CI 2.3-11.5), as well as females ages 18 to . The risks and outcomes of myocarditis after COVID-19 vaccination are unclear. Careers. (2022). mmwrq@cdc.gov. View Large Download. Most people (95%) who develop myocarditis after receiving a COVID-19 mRNA vaccine have only mild symptoms that go away within a few days. FDA requires that vaccine providers report to VAERS vaccination administration errors, serious adverse events, cases of multisystem inflammatory syndrome, and cases of COVID-19 that result in hospitalization or death after administration of a COVID-19 vaccine under an EUA. Information regarding the risk for myocarditis with mRNA COVID-19 vaccines should be disseminated to providers to share with vaccine recipients. Patients can usually return to their normal daily activities after their symptoms improve. All HTML versions of MMWR articles are generated from final proofs through an automated process. Incidence Rates and Rate Ratios of Myocarditis in Vaccinated Individuals Compared With Control Groups. (Jolygon/iStock via Getty Images) The risk of developing myocarditis - an inflammation of the heart muscle - following a booster dose of the Pfizer COVID-19 vaccine is low, according to new research from Israel. https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/risk-benefit-analysis.html. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Am J Cardiol 2021;149:95102. Follow-up is ongoing to identify and understand longer-term outcomes after myocarditis occurring after COVID-19 vaccination. Reported cases of the rare heart . CDC and FDA will continue to closely monitor reports of myocarditis after receipt of the mRNA COVID-19 vaccines and will bring any additional data to ACIP for consideration. There were 13.3 cases of myocarditis per 100,000 in people 12 to 29 years old who got Moderna's vaccine compared to 2.7 cases per 100,000 people in that age group that got the Pfizer vaccine. Moderna - 19 case of myocarditis and 19 cases of pericarditis out of 20 million doses given Five people died. The known risks of COVID-19 illness and its related, possibly severe complications, such as long-term health problems, hospitalization, and even death, far outweigh the potential risks of having a rare adverse reaction to vaccination, including the possible risk of myocarditis or pericarditis. URL addresses listed in MMWR were current as of MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services. <>/Metadata 2557 0 R/ViewerPreferences 2558 0 R>> References to non-CDC sites on the Internet are CDC also encourages reporting of any additional clinically significant adverse event, even if it is not clear whether a vaccination caused the event. Moderna said the majority of the infections were mild. Key factors to consider are the current rates of COVID-19 infection, the childs overall health, and the parents assessment of risks. However, the balance of benefits and risks varied by age and sex because cases of myocarditis were primarily identified among males aged <30 years, and the risks of poor outcomes related to COVID-19 increase with age. The CONNECTS-Collaborative Cohort of Cohorts for COVID-19 Research (CONNECTS-C4R) trial is enrolling 50,000 people to determine factors that may predict disease severity and long-term side effects of COVID-19. The scientists are monitoring the health of a diverse group of people to learn about the long-term effects of COVID, including heart problems. Among recipients of either vaccine, there were only 13 reports or less of myocarditis beyond 10 days for any individual time from vaccination to symptom onset. Lancet. Feelings of having a fast-beating, fluttering, or pounding heart Myocarditis and pericarditis have rarely been reported. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html. JAMA Netw Open. Design, setting, and participants: Comparison of MIS-C Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children. According to the TGA, the current overall estimated rates for the entire population of myocarditis for Pfizer and Moderna are similar - 1.4 cases per 100,000 Pfizer doses versus 1.8 cases per 100,000 Moderna doses. The EUA has been modified to include information on myocarditis after receipt of mRNA COVID-19 vaccines. Learn more about, Feelings of having a fast-beating, fluttering, or pounding heart. Chou, O., Zhou, J., Lee, T., Kot, T., Lee, S., Wai, A., Wong, W. T., Zhang, Q., Cheng, S. H., Liu, T., Vassiliou, V. S., Cheung, B., & Tse, G. (2022). Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. endobj They suggest the rates of myocarditis after the Moderna-NIAID vaccine may be two-and-a-half times higher. Saving Lives, Protecting People, Given new evidence on the B.1.617.2 (Delta) variant, CDC has updated the, The White House announced that vaccines will be required for international travelers coming into the United States, with an effective date of November 8, 2021. Unauthorized use of these marks is strictly prohibited. Disclaimer. Acute clinical courses were generally mild; among 304 hospitalized patients with known clinical outcomes, 95% had been discharged at time of review, and none had died. An official website of the United States government. Treatment is often given in a hospital. The work group also reviewed a benefit-risk assessment of myocarditis events after receipt of mRNA COVID-19 vaccines, considering recent epidemiology of COVID-19 and sequelae of COVID-19, including myocarditis and multisystem inflammatory syndrome in children (MIS-C). Myocarditis reporting rates were 40.6 cases per million second doses of mRNA COVID-19 vaccines administered to males aged 1229 years and 2.4 per million second doses administered to males aged 30 years; reporting rates among females in these age groups were 4.2 and 1.0 per million second doses, respectively. Members of the Advisory Committee on Immunization Practices COVID-19 Vaccines Safety Technical Work Group: Robert Hopkins, National Vaccine Advisory Committee; Kathryn Edwards, Vanderbilt University School of Medicine; Lisa Jackson, Kaiser Permanente Washington Health Research Institute; Jennifer Nelson: Kaiser Permanente Washington Health Research Institute; Laura Riley, American College of Obstetricians and Gynecologists; Patricia Whitley-Williams, National Medical Association; Tatiana Beresnev, National Institutes of Health; Karen Farizo, Food and Drug Administration; Hui Lee Wong, Food and Drug Administration; Judith Steinberg, U.S. Department of Health and Human Services; Matthew Clark, Indian Health Service; Mary Rubin, Health Resources & Services Administration; Fran Cunningham, Veterans Administration; Limone Collins, Department of Defense. Chavda VP, Bezbaruah R, Valu D, Patel B, Kumar A, Prasad S, Kakoti BB, Kaushik A, Jesawadawala M. Vaccines (Basel). Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrncir D, Herring K, Platzer M, Adams N, Sanou A, Cooper LT Jr. JAMA Cardiol. In a population-based cohort study of adolescents and adults in Denmark who received two doses of the same mRNA vaccine against COVID, the risk of myocarditis or myopericarditis within 28 days. Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. After reports of myocarditis and pericarditis in mRNA vaccine recipients, which predominantly occurred in young males after the second dose, an ACIP meeting was rapidly convened to review reported cases of myocarditis and pericarditis and discuss the benefits and risks of mRNA COVID-19 vaccination in the United States. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Page last updated: NHLBI-supported research aims to identify the causes of lasting heart and lung symptoms of COVID-19, find ways to prevent these problems, and improve treatment to promote rapid healing. The researchers found only 1 case per 71,400 vaccinated with Pfizer-BioNTech and 1 case per 23,800 vaccinated with Moderna. Importance: myocarditis and pericarditis and the mRNA COVID-19 vaccines, made by Moderna and Pfizer-BioNTech, in some vaccine recipients. Myocarditis and pericarditis have rarely been reported. Figure 1.. Cases of Myocarditis After mRNA-Based, Figure 1.. Cases of Myocarditis After mRNA-Based COVID-19 Vaccination by Age at Onset of Myocarditis, Figure 2.. Cases of Myocarditis After mRNA-Based, Figure 2.. Cases of Myocarditis After mRNA-Based COVID-19 Vaccination by Time From Vaccination to Symptom, MeSH Baggs J, Gee J, Lewis E, et al. Vaccinating adolescents against SARS-CoV-2 in England: a risk-benefit analysis. In the past few weeks, anti-vaxxers have rallied behind a nonpeer-reviewed study by a group of Canadian researchers as evidence against COVID-19 vaccines. official website and that any information you provide is encrypted